RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced preclinical data from its proprietary adeno-associated virus (AAV) capsid variant, STAC-BBB, that demonstrated robust penetration of the blood-brain barrier (BBB) and strong transgene expression throughout the central nervous system (CNS) of NHPs when administered intravenously at clinically-relevant doses, outperforming results obtained by Sangamo for other known neurotropic capsid vari ...

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that the company has scheduled the release of its fourth quarter and full year 2023 financial results before the market opens on Wednesday, March 13, 2024. The Company will hold a conference call at 4:30 p.m. Eastern on Wednesday, March 13, which will be open to the public. During the conference call, the company will review its financial results and provide business updates. Participa ...

Exhibit 99.1 SANGAMO THERAPEUTICS REPORTS RECENT BUSINESS HIGHLIGHTS AND FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL RESULTS Richmond, California, March 13, 2024 – Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today reported recent business highlights and fourth quarter and full year 2023 financial results, including meaningful data to support advancement of its neurology pipeline. "In 2023, Sangamo announced the prioritization of its pipeline programs that support our focus as a n ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________________________________________________ Form 10-K _______________________________________________________________________________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the trans ...

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced important U.S. and European regulatory updates for isaralgagene civaparvovec, or ST-920, its wholly owned gene therapy product candidate for the treatment of Fabry disease. The FDA has agreed in a Type D meeting that data from a single, adequate, and well-controlled study may form the primary basis of approval of a BLA for isaralgagene civaparvovec. The proposed study would enroll up to ...

RICHMOND, Calif.--(BUSINESS WIRE)--Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced updated preliminary data from the Phase 1/2 STAAR clinical study evaluating isaralgagene civaparvovec, or ST-920, a wholly owned gene therapy product candidate for the treatment of Fabry disease. In the largest known clinical gene therapy program in Fabry disease to date, data from 24 patients continued to show durable safety and preliminary efficacy data as of the data cutoff date, whic ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Louise Wilkie - Vice President-Investor Relations and Corporate Communications Sandy Macrae - Chief Executive Officer Nathalie Dubois-Stringfellow - Chief Development Officer Mark McClung - Chief Operating Officer Jason Fontenot - Chief Scientific Officer Prathyusha Duraibabu - Chief Financial Officer Amy Pooler - Head of Research Conference Call Participants Reena Patel - RBC Capital M ...

Forward-Looking Statements Pioneering and Delivering the Future of Genomic Medicines This presentation contains forward-looking statements regarding our current expectations. These forward-looking statements include, without limitation, statements relating to our focus on epigenetic regulation and delivery engineering, the potential to develop, obtain regulatory approvals for and commercialize durable, safe and effective therapies to treat certain diseases and the timing, availability and costs of such ther ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________________________________________ FORM 10-Q ________________________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 000-30171 __ ...

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q2 2023 Earnings Conference Call August 8, 2023 4:30 PM ET Company Participants Louise Wilkie – Vice President-Investor Relations and Corporate Communications Sandy Macrae – Chief Executive Officer Nathalie Dubois-Stringfellow – Chief Development Officer Mark McClung – Chief Operating Officer Jason Fontenot – Chief Scientific Officer Prathyusha Duraibabu – Chief Financial Officer Lisa Rojkjaer – Chief Medical Officer Conference Call Participants Maury Raycroft – Jeff ...